Diagnostics Solutions Strategic Priorities slide image

Diagnostics Solutions Strategic Priorities

Roche is an IVD market leader in cardiovascular diseases Highest benefit class and evidence level in major cardiac guidelines Roche Core Lab cardiovascular market share in 2019¹ Clinical practice guidelines⁹ 34% Roche 19% 17% SIEMENS Healthineers Abbott A Promise for Life 9% QUIDEL 6% ① DANAHER 16% Others Elecsys Troponin T Gen 5 STAT Elecsys and A cobas e analyzers IVD "Redefining the gold standard of myocardial infarction using Troponin T" • Diagnosis²,3 • Risk prediction 2,3 cobas . Early invasive strategy² "NT-proBNP: The gold standard biomarker in heart failure"7 • • Diagnosis 5,6 Prognosis6 - 1 Source Roche Diagnostics with BBC; 2 Roff M et al, Eur Heart J 2016; 37: 267; 3 Amsterdam EA et al., Circulation 2014;130:2354; 4 Ohman EM. Clin Chem 2017; 63: 429; 5 Ponikowski P et al., Eur Heart J 2016; 37:2129; 6 Yancy CW et al, Circulation. 2017;136:e137; 7 McKie PM et al, J Am Coll Cardiol 2016;68:2437; 8 American College of Cardiology / American Heart Association 56
View entire presentation